scispace - formally typeset
L

Leif Bertilsson

Researcher at Karolinska University Hospital

Publications -  321
Citations -  24620

Leif Bertilsson is an academic researcher from Karolinska University Hospital. The author has contributed to research in topics: Debrisoquine & Debrisoquin. The author has an hindex of 87, co-authored 321 publications receiving 23933 citations. Previous affiliations of Leif Bertilsson include Astra & University of Oulu.

Papers
More filters
Journal ArticleDOI

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.

TL;DR: Many drugs, including proton pump inhibitors and certain antidepressants, are metabolized by the polymorphic cytochrome P450 (CYP) 2C19 enzyme, and a significant portion of extensive metabolizers do not reach appropriate drug levels.
Journal ArticleDOI

Monoamine metabolites in CSF and suicidal behavior.

TL;DR: A follow-up study revealed a 20% mortality by suicide within a year after lumbar puncture in patients with a CSF-HIAA level below the median, which was lower than normal in suicidal patients who were not diagnosed as depressed at the time of lumbr puncture.
Journal ArticleDOI

"Serotonin depression"--a biochemical subgroup within the affective disorders?

TL;DR: There was a significant correlation between the concnetration of 5-HIAA and severity of depression in the lower, but not in the upper, mode, which suggests the existence of a biochemical subgroup of depressive disorder, characterized by a disturbance of serotonin turnover.
Journal ArticleDOI

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

TL;DR: The data show the principle of inherited amplification of an active gene, and the finding of a specific haplotype with two or more active CYP2D6 genes allows genotyping for ultrarapid drug metabolizers.
Journal ArticleDOI

Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs

TL;DR: The present-day knowledge on the influence of the genetic variability in CYP2D6 on the clinical pharmacokinetics and therapeutic effects/adverse effects of psychotropic drugs is reviewed.